1. Articles in category: Human Interest

    1-24 of 182 1 2 3 4 5 6 7 8 »
    1. Epigenetic analysis: Giving the right name to a tumor

      Epigenetic analysis: Giving the right name to a tumor

      ( Heidelberg University Hospital and Medical Faculty ) Scientists from the 'Hopp Children's Cancer Center at the NCT Heidelberg' (KiTZ) and the Neuropathology Department at Heidelberg University Hospital have substantially enhanced the classification of tumors of the central nervous system (CNS) / Physicians will now be able to categorize CNS tumors more precisely into specific risk groups and make therapy decisions on this basis / The method was developed in close collaboration with the German Cancer Consortium (DKTK) / Publication in Nature.

      Read Full Article
    2. A molecular map of childhood cancers

      A molecular map of childhood cancers

      Researchers led by Professor Stefan Pfister from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have been able to draw an extremely detailed molecular map of childhood cancers. In close collaboration with the German Cancer Consortium (DKTK) and the Society for Pediatric Oncology and Hematology (GPOH), they screened almost 1,000 tumor samples from […]

      The post A molecular map of childhood cancers appeared first on Healthcanal.com.

      Read Full Article
      Mentions: GPOH Genetics
    3. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      PLoS Med. 2018 Feb;15(2):e1002505

      Authors: Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J

      Read Full Article
    4. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    5. Fertility preservation options in pediatric and adolescent patients with cancer.

      Fertility preservation options in pediatric and adolescent patients with cancer.

      Cancer. 2018 Jan 25;:

      Authors: Burns KC, Hoefgen H, Strine A, Dasgupta R

      Abstract The incidence of childhood cancer has steadily increased since the 1950s, with approximately 16,000 children diagnosed each year. However, with the advent of more effective multimodal therapies, childhood cancer survival rates have continued to improve over the past 40 years, with >80% of patients now surviving into adulthood.

      Read Full Article
    6. Microbiome predicts blood infections in pediatric cancer patients

      Microbiome predicts blood infections in pediatric cancer patients

      Cancer patients receive essential medicines, fluids, blood and nutrients through long, flexible tubes called central venous catheters, or central lines. But every year in the United States, these central lines are associated with an estimated 400,000 blood infections, many of which are fatal, and which cost the healthcare system upwards of $18 billion dollars annually. But what if some or even many of these infections aren't, in fact, introduced by central lines?

      Read Full Article
    7. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      The European Commission has...

      Read Full Article
    8. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      Read Full Article
    9. Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors.

      Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors.

      Pediatr Radiol. 2017 Dec 19;:

      Authors: Sirignano M, Dillman JR, Weiss BD, Quinn CT, Zhang B, Su W, Trout AT

      Abstract BACKGROUND: Reticuloendothelial system MRI signal hypointensity is common in pediatric oncology patients with solid abdominal tumors.

      Read Full Article
      Mentions: Imaging Bone Marrow
    10. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Drugs Today (Barc). 2017 Sep;53(9):469-476

      Authors: Greenwood K, Foster JH

      Abstract Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy.

      Read Full Article
      Mentions: Antibody Treatment
    11. The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.

      The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.

      Front Immunol. 2017;8:1640

      Authors: Le TP, Thai TH

      Abstract Research on adult cancer immunotherapy is proceeding at a rapid pace resulting in an impressive success rate exemplified by a few high profile cases. However, this momentum is not readily extended to pediatric immunotherapy, and it is not for lack of trying.

      Read Full Article
      Mentions: Immunotherapy
    12. Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

      Read Full Article
      Mentions: Treatment GvHD
    13. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      J Pediatr Surg. 2017 Nov 09;:

      Authors: Amano H, Uchida H, Tanaka Y, Tainaka T, Mori M, Oguma E, Kishimoto H, Kawashima H, Arakawa Y, Hanada R, Koh K

      Read Full Article
    14. New developments in immunotherapy for pediatric solid tumors.

      New developments in immunotherapy for pediatric solid tumors.

      Curr Opin Pediatr. 2017 Nov 20;:

      Authors: Schultz LM, Majzner R, Davis KL, Mackall C

      Abstract PURPOSE OF REVIEW: Building upon preclinical advances, we are uncovering immunotherapy strategies that are translating into improved outcomes in tumor subsets. Advanced pediatric solid tumors carry poor prognoses and resultant robust efforts to apply immunotherapy advances to pediatric solid tumors are in progress.

      Read Full Article
      Mentions: Immunotherapy
    15. Surgical Treatment of Neuroblastoma.

      Surgical Treatment of Neuroblastoma.

      Isr Med Assoc J. 2017 Nov;19(11):691-695

      Authors: Ben Barak A, Golan H, Waldman D, Arkovitz MS

      Abstract BACKGROUND: Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question. OBJECTIVES: To examine our experience with surgical resection of neuroblastoma.

      Read Full Article
      Mentions: Treatment
    16. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Anticancer Res. 2017 11;37(11):5911-5918

      Authors: Berger M, VON Schweinitz D

      Abstract Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor.

      Read Full Article
    17. Immune Thrombocytopenia in a Child with Neuroblastoma.

      Immune Thrombocytopenia in a Child with Neuroblastoma.

      Case Rep Pediatr. 2017;2017:1329489

      Authors: Ikizoglu HT, Ayan I, Tokat F, Tecimer T, Topuzlu Tekant G

      Abstract Thrombocytopenia is a frequent finding in patients with solid tumors. It is usually caused by bone marrow infiltration or by myelosuppression due to anticancer therapy; however immune thrombocytopenia (ITP) associated with solid tumors is rare. Neuroblastoma is the most common extracranial solid tumor in children.

      Read Full Article
      Mentions: Bone Marrow
    18. WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.

      WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.

      Cell Mol Life Sci. 2017 Oct 22;:

      Authors: Becker J, Wilting J

      Abstract Neuroblastoma (NB) is a tumor of the sympathoadrenal system arising in children under 15 years of age. In Germany, NB accounts for 7% of childhood cancer cases, but 11% of cancer deaths.

      Read Full Article
    19. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Pediatr Hematol Oncol. 2017 Oct 17;:1-11

      Authors: Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan LC

      Abstract BACKGROUND: Childhood neuroblastoma describes a heterogeneous group of extracranial solid tumors, that are treated per risk profile. We sought to describe treatment patterns and survival using population-based data from throughout the United States.

      Read Full Article
      Mentions: Treatment COG MYCN
    1-24 of 182 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles